Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
1. 请及时下载文件确认是否正确, 系统将在 2025-07-18 21:23:03 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1001/jamaoncol.2023.1363
文献链接: https://jamanetwork.com/journals/jamaoncology/fullarticle/2805681
其他信息:
出版社: American Medical Association (AMA)
作者: Lili Mao; Bin Lian; Caili Li; Xue Bai; Li Zhou; Chuanliang Cui; Zhihong Chi; Xinan Sheng; Xuan Wang; Bixia Tang; Xieqiao Yan; Siming Li; Yan Kong; Jie Dai; Xiaoting Wei; Juan Li; Rong Duan; Huayan Xu; Xiaowen Wu; Yue Yang; Fengzhuo Cheng; Cheng Zhang; Fangzhou Xia; Zheng Pang; Jun Guo; Lu Si
